



Ifu

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lu et al.
Serial No. : 10/789,247
Filed : February 27, 2004
Title : COMPOSITIONS AND METHODS FOR CYTOMEGALOVIRUS TREATMENT

Art Unit : 1616
Examiner : Unknown

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and non-patent literature are enclosed. Also enclosed is a copy of an International Search Report dated January 7, 2005, which was received in a related PCT application, PCT/US04/05923. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

This statement is being filed before the receipt of a first Office Action on the merits. No fees are believed to be due. Please apply any charges or credits to Deposit Account No. 06-1050, referencing attorney docket no. 07917-190001.

Respectfully submitted,

Date: _____

April 7, 2005

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

21025895.doc

J. Peter Fasse

J. Peter Fasse
Reg. No. 32,983

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit


April 7, 2005

Signature

Mary J. Zynda

Typed or Printed Name of Person Signing Certificate

Mary J. Zynda



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-190001	Application No. 10/789,247
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Lu et al.	
		Filing Date February 27, 2004	Group Art Unit 1616

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	A1	5,552,143	Sept. 3, 1996	Plotkin et al.			
	A2	5,591,439	Jan. 7, 1997	Plotkin et al.			
	A3	5,720,957	Feb. 24, 1998	Jones et al.			
	A4	5,728,578	Mar. 17, 1998	Jahn et al.			
	A5	5,800,981	Sept. 1, 1998	Bruggeman et al.			
	A6	5,846,733	Dec. 8, 1998	Jahn et al.			
	A7	6,448,389	Sep. 10, 2002	Gonczol et al.			
	A8						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	B1	EP 0 389 286 B1	26/09/1990	Europe				
	B2	EP 0 252 531 B	02/12/1992	Europe			X (abstract)	
	B3	WO 97/40165	30/10/1997	WIPO				
	B4	EP 0 236 145	09/09/1987	Europe				
	B5	WO 01/72782	04/10/2001	WIPO				
	B6	WO 02/34769	02/05/2002	WIPO				
	B7							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	C1	Adler et al., "A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne)," J. Infect. Dis. 180(3):843-6 (1999)
	C2	Berencsi et al., "A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects," J. Infect. Dis. 183(8):1171-9 (2001)
	C3	Britt and Alford, "Cytomegalovirus," Fields Virology, 3d Ed., Chapter 77:2493-2523 (1996)
	C4	Cull et al., "Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice," Gene Ther. 9(20):1369-78 (2002)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-190001	Application No. 10/789,247
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Lu et al.	
		Filing Date February 27, 2004	Group Art Unit 1616

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	C5	Endresz et al., "Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization," Vaccine 17:50-58 (1999)
	C6	Endresz et al., "Optimization of DNA immunization against human cytomegalovirus," Vaccine 19:3972-80 (2001)
	C7	La Rosa et al., "Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice," Blood 100(10):3681-3689 (2002)
	C8	Lu et al., "Antigen Engineering in DNA Immunization," Methods in Molecular Medicine 29:355-74 (2000)
	C9	Mach et al., "Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73)," J. Virol. 74(24):11881-92 (2000)
	C10	Morello et al., "Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication," J. Virol. 76(10):4822-35 (2002)
	C11	Temperton, "DNA vaccines against cytomegalovirus: current progress," Intl. J. Antimicrobial Agents 19:169-72 (2002)
	C12	Oh et al., "Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery," Vaccine 19(31):4519-25 (2001)
	C13	S.A. Plotkin, "Vaccination against cytomegalovirus," Arch. Virol. 17:121-34 (2001)
	C14	Scholl et al., "Prokaryotic expression of immunogenic polypeptides of the large phosphoprotein (pp150) of human cytomegalovirus," J. Gen. Virol. 69 (Pt 6):1195-204 (1988)
	C15	Spaete et al., "Coexpression of Truncated Human Cytomegalovirus gH with the UL115 Gene Product or the Truncated Human Fibroblast Growth Factor Receptor Results in Transport of gH to the Cell Surface," Virology 193(2):853-61 (1993)
	C16	Walker et al., "Characterization of Human Cytomegalovirus Strains by Analysis of Short Tandem Repeat Polymorphisms," J. Clin. Microbio. 39:2219-26 (2001)
	C17	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	